Ricevi le ultime notizie sulle azioni Mainz Biomed con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MYNZ

Ultime notizie per

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed NV

Press Releases

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

News

Financing

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Health Care

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

General

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland

Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

MYNZ

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Alzamend Neuro

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

enGene Holdings

Ensysce Biosciences

Entero Therapeutics

Ernexa Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

Genprex

HCW Biologics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Maxim Group

JonesTrading

Screenshot 2025-04-15 at 7.03.21 PM

Biotech

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2025-04-02 at 9.29.30 PM

Mainz BioMed&#39;s Trial To Bring Critical Early Cancer Detection One Step Closer

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Screenshot 2024-11-11 at 7.48.49 PM

What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer

Screenshot 2024-10-04 at 11.57.48 PM

Interview

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

Screenshot 2024-09-04 at 5.52.15 PM

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Screenshot 2024-08-30 at 2.55.26 PM

Emerging Markets

Markets

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Screenshot 2024-08-30 at 6.27.59 PM

EXAS

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Comments

Mainz Biomed Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO